BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
03 Maio 2024 - 8:00AM
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring”
or the “Company”), a clinical-stage global biopharmaceutical
company focused on developing innovative cancer therapies, today
announced it will host a Research and Development (R&D) Day to
discuss the current unmet medical needs and the potential of
Plinabulin as a novel immunochemotherapeutic in drug combinations
and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at
10:00 a.m. ET.
The conference call and webinar will feature presentations by
Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D. (Piedmont
Cancer Institute), Alberto Chiappori, M.D. (Moffitt Cancer Center),
and Steven Lin, M.D. (MD Anderson Cancer Center), who will discuss
below topics:
- Plinabulin history and development strategy for cancer
- Plinabulin’s immunomodulatory activity as a DC maturation
agent
- Unmet needs after immune-checkpoint-inhibitor failure
Also featured will be a management discussion on technology
platform and pipeline updates of SEED Therapeutics, BeyondSpring’s
majority-owned molecular glue subsidiary.
The dial in numbers for the conference call are 1-877-407-0779
(U.S.) or 1-201-389-0914 (international). To register for the
webinar, please click here. An archived replay of the webinar will
be available following the presentation on BeyondSpring’s website
www.beyondspringpharma.com under “Events and Presentations” in the
Investors section.
Trevor M. Feinstein, M.D.Dr. Feinstein is board
certified in medical oncology and hematology. He joined Piedmont
Cancer Institute in 2011 and is the Director of Research at
Piedmont Fayette Hospital. Dr. Feinstein is actively involved in
clinical trials focused on improved therapies for various cancers.
He is a member of Georgia CORE’s research committee along with
Georgia Society for Clinical Oncology Clinical Practice Committee.
He also chairs the Lung Disease Group for the entire OneOncology
network. He is a co-investigator on several peer-reviewed research
projects and has authored numerous publications and abstracts in
Hematology and Oncology. Dr. Feinstein graduated from the
University of Illinois medical school and completed his residence
and fellowships at the University of Pittsburgh.
Alberto Chiappori, M.D.Dr. Chiappori is board
certified in medical oncology. He serves as senior member of
oncology and medicine for the Thoracic Oncology Program at the H.
Lee Moffitt Cancer Center and Research Institute in Tampa and
Florida. Dr. Chiappori is an active member of the American Society
of Clinical Oncology, the European Society of Medical Oncology, the
American Association for Cancer Research, and the International
Association for the Study of Lung Cancer (IASLC). Dr. Chiappori
received his MD from the Universidad Peruana Cayetano Heredia in
Lima, Peru, completed his residency at Southern Illinois University
School of Medicine in Springfield, Illinois, and finished his
fellowship and senior fellowship in medical oncology-hematology at
Vanderbilt University School of Medicine in Nashville,
Tennessee.
Steven Lin, M.D., Ph.D.Dr. Lin is a Professor
and Physician-Scientist at MD Anderson Cancer Center, with joint
appointments in the Departments of Radiation Oncology and
Experimental Radiation Oncology. Dr. Lin’s practice focuses on
thoracic malignancies, and he oversees several clinical trials
including the use of proton beam therapy for esophageal cancer and
in the combination of immunotherapy with radiotherapy in lung and
esophageal cancers. Dr. Lin runs a translational research team that
evaluates biomarkers for treatment response and disease outcomes
after cancer therapy. Dr. Lin acquired his M.D. and Ph.D. in the
Medical Scientist Training Program at the University of California
Irvine Medical School. He went on for residency training in
Radiation Oncology at The Johns Hopkins Hospital.
About BeyondSpringBeyondSpring
is a global clinical-stage biopharmaceutical company focused on
developing innovative therapies to improve clinical outcomes for
patients with high unmet medical needs. The Company is advancing
its first-in-class lead asset, Plinabulin, as a direct anti-cancer
agent in various cancer indications and to prevent
chemotherapy-induced neutropenia. BeyondSpring’s pipeline also
includes three preclinical immuno-oncology assets. Additionally,
BeyondSpring’s subsidiary, SEED Therapeutics, leverages a
proprietary TPD drug discovery platform and has an initial R&D
collaboration with Eli Lilly. Learn more by visiting
https://beyondspringpharma.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release includes forward-looking
statements that are not historical facts. Words such as “will,”
“expect,” “anticipate,” “plan,” “believe,” “design,” “may,”
“future,” “estimate,” “predict,” “objective,” “goal,” or variations
thereof and variations of such words and similar expressions are
intended to identify such forward-looking statements.
Forward-looking statements are based on BeyondSpring’s current
knowledge and its present beliefs and expectations regarding
possible future events and are subject to risks, uncertainties, and
assumptions. Actual results and the timing of events could differ
materially from those anticipated in these forward-looking
statements as a result of several factors including, but not
limited to, our ability to continue as a going concern,
difficulties raising the anticipated amount needed to finance the
Company’s future operations on terms acceptable to the Company, if
at all, unexpected results of clinical trials, delays or denial in
regulatory approval process, results that do not meet the Company’s
expectations regarding the potential safety, the ultimate efficacy
or clinical utility of the Company’s product candidates, increased
competition in the market, the Company’s ability to meet Nasdaq's
continued listing requirements, and other risks described in
BeyondSpring’s most recent Form 20-F on file with the U.S.
Securities and Exchange Commission. All forward-looking statements
made herein speak only as of the date of this release and
BeyondSpring undertakes no obligation to update publicly such
forward-looking statements to reflect subsequent events or
circumstances, except as otherwise required by law.
Investor
Contact:IR@beyondspringpharma.com
Media
Contact:PR@beyondspringpharma.com
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024